- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
OVD earns CE mark
Abbott Medical Optics (AMO) has expanded its line of ophthalmic viscosurgical devices (OVDs) after receiving the European CE mark for a clear, viscous, low molecular weight dispersive OVD (Healon EndoCoat OVD).
Santa Ana, CA-Abbott Medical Optics (AMO) has expanded its line of ophthalmic viscosurgical devices (OVDs) after receiving the European CE mark for a clear, viscous, low-molecular-weight dispersive OVD (Healon EndoCoat).
The proprietary dispersive OVD is intended for use as a surgical aid in cataract extraction, IOL implantation, corneal transplantation, and glaucoma filtration surgery. It can be delivered through a 25-gauge cannula and may be used in combination with other proprietary OVDs from the same manufacturer.
Dispersive OVDs are expected to account for 38% of the total OVD market in 2011, according to independent ophthalmic research firm Market Scope.
The OVD is available in Europe, Canada, and New Zealand, and it is currently under review by the FDA. The company expects shipments to other geographic areas to follow once it receives necessary regulatory approvals. Customers who already receive regular shipments of another proprietary intraocular injectable solution (Vitrax II, AMO) automatically will undergo transition to this dispersive OVD when it is approved in their areas.
